Lexicon Pharmaceuticals, Inc. (LXRX) is a publicly traded Healthcare sector company. As of May 21, 2026, LXRX trades at $2.22 with a market cap of $950.58M and a P/E ratio of -31.07. LXRX moved +4.23% today. Year to date, LXRX is +93.86%; over the trailing twelve months it is +287.72%. Its 52-week range spans $0.28 to $2.53. Analyst consensus is strong buy with an average price target of $4.03. Rallies surfaces LXRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Lexicon Pharmaceuticals Delivers $0.00 Q1 EPS, Beats $0.04 Loss Estimate: Lexicon Pharmaceuticals reported Q1 EPS of $0.00, surpassing the Zacks Consensus Estimate of a $0.04 loss and improving from a $0.07 loss in Q1 2025. The result represents a 100% year-over-year swing in quarterly EPS performance.
| Metric | Value |
|---|---|
| Price | $2.22 |
| Market Cap | $950.58M |
| P/E Ratio | -31.07 |
| EPS | $-0.07 |
| Dividend Yield | 0.00% |
| 52-Week High | $2.53 |
| 52-Week Low | $0.28 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $69.64M |
| Net Income | $-26.09M |
| Gross Margin | 99.50% |
4 analysts cover LXRX: 0 strong buy, 3 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $4.03.